Is natalizumab a breakthrough in the treatment of multiple sclerosis?

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 6, 2003, Pages 999-1001

  Doggrell, Sheila A ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Multiple sclerosis; Natalizumab

Indexed keywords

ALPHA4 INTEGRIN; BETA INTERFERON; CORTICOSTEROID; GADOLINIUM; GLATIRAMER; INTERFERON; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; NATALIZUMAB; PLACEBO;

CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; REVIEW; SIDE EFFECT;

ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 0038009038     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.6.999     Document Type: Review

References (10)

1. MILLER DH, KHAN OA, SHEREMATA WA et al.: A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2003) 348:15-23.
2. FILIPPINI G, MUNARI L, INCORVAIA B et al.: Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet (2003) 361:545-552.
3. 4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J. Neuroimmunol. (1995) 58:1-10.
4. 4 integrin antibody on brain lesion activity in MS. Neurology (1999) 53:466-472.
5. KURTZKE JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33:1444-1452.
6. COMI G, FILIPPI M, WOLINSKY JS: European/Canadian multicenter, double-blind randomized placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol. (2001) 49:290-297.
7. 1a subcutaneously in multiple sclerosis) study group. Lancet (1998) 352:1498-1504.
8. GALETTA SL, MARKOWITZ C, LEE AG: Immunomodulatory agents for the treatment of relapsing multiple sclerosis. A systematic review. Arch. Intern. Med. (2002) 162:2161-2169.
9. 1a in relapsing MS. The PRISM study group and the university of British Columbia MS/MRI analysis group, PRISM-4. Neurology (2001) 56:1628-1636.
10. ZHANG J, HUTTON G, ZANG Y: A comparison of the mechanisms of action of interferon-β and glatiramer acetate in the treatment of multiple sclerosis. Clin. Ther. (2002) 12:1998-2021.